Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7471956 | 0.94 | CHRNA7 (0.40) | CHRNA7HIF1ATRAP1CYP3A4HTT | |
| SCHEMBL22664417 | 0.81 | CYP3A4 (0.38) | CYP3A4HTTSMN1; SMN2 | |
| Bromide SCHEMBL6693614 | 0.81 | CHRNA7 (0.43) | CHRNA7HIF1ATRAP1 | |
| Bromide SCHEMBL9152371 | 0.80 | ALDH1A1 (0.33) | CHRNA7CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL24312364 | 0.80 | SMN1; SMN2 (0.40) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL5488886 | 0.80 | LTA4H (0.42) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL22664485 | 0.79 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL22664446 | 0.79 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL22664504 | 0.79 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL22664491 | 0.79 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |